Aptar Appoints Julie Xing to its Board of Directors

Rhea-AI Summary

AptarGroup, Inc. (NYSE: ATR) announced the appointment of Julie Xing to its Board of Directors. With over 20 years of experience in sectors like pharmaceuticals and medtech, Julie aims to inspire sustainable growth in challenging markets. She previously served as Executive Chair of Mundipharma China and held various leadership roles at Eli Lilly. Aptar's President and CEO, Stephan B. Tanda, emphasized the value of her insights into the pharmaceutical market, particularly in Asia. The company celebrates diversity on its board, with 45% female representation. Julie holds a Ph.D. in Biology from Hong Kong University.

Positive

• Julie Xing's extensive experience in pharmaceuticals and medtech may bring valuable insights to Aptar.
• Her appointment enhances Aptar's board diversity, potentially appealing to socially conscious investors.

Negative

• Concerns may arise regarding the continuity of leadership and experience gaps among board members.

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)-- AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, announced today that Julie Xing has joined its Board of Directors.

Julie Xing Joins Aptar’s Board of Directors (Photo: Aptar)

With over 20 years of experience in pharmaceutical, medtech, digital health, biotech and diagnosis, Julie’s leadership approach focuses on inspiring teams to deliver sustainable growth in challenging markets and healthcare environments. With her solid track record of business transformation in multiple global positions, Julie is recognized as a highly engaging multi-cultural leader skilled in fluidly partnering with cross-functional teams to deliver results.

Since 2022, Julie has served as Executive Chair of the Board of Directors of Mundipharma China. Mundipharma is a global pharmaceutical leader. Prior to that, Julie held the position of Global Senior Vice President, President of Greater China for Envista Holdings Corporation. Julie’s breadth of experience also includes numerous leadership roles at Eli Lilly and Company, including Senior Director, Global New Product Planning and Payer Marketing, Pricing, Reimbursement and Access of Lilly Diabetics and Vice President, Corporate and Government Affairs and Market Access and Vice President of Lilly China Oncology, while based in Shanghai. Prior to Eli Lilly, Julie was Vice President and General Manager of Asia Pacific and Japan Operations at Panomics and Affymetrix, which was acquired by Thermo Fisher Scientific.

In addition, she has served as Board Advisor on the Board of Directors for Mars, a global manufacturer of confectionery, pet food and provider of animal care services, since 2019.

“We are pleased to welcome Julie Xing to our Board of Directors. Julie’s board leadership acumen, along with her in depth knowledge of the pharmaceutical market and the Asia region, makes her a valuable addition to Aptar’s Board of Directors,” said Stephan B. Tanda, Aptar President and CEO.

Julie Xing said, “Aptar is an industry leader with a deep portfolio of products and services that spans many different and attractive pharmaceutical and consumer end markets. I am excited to join Aptar’s Board of Directors to build upon the Company’s more than 75-year history of developing innovative products that millions of people around the world use every day.”

George Fotiades, Chairman of Aptar’s Board of Directors, stated, “We look forward to welcoming Julie to our highly talented, diverse and multi-cultural Board of Directors. With 45% of our Board consisting of women and 27% of our Board comprised of persons of color, we are proud to be a leading company for greater diversity and gender equality on corporate boards.”

Julie holds a Ph.D. in Biology from the Hong Kong University of Science and Technology.

About Aptar

Aptar is a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions and services. Aptar’s innovative solutions and services serve a variety of end markets including pharmaceutical, beauty, food, personal care, home care and beverage. Using insights, proprietary design, engineering and science to create dispensing, dosing and protective technologies for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has 13,500 dedicated employees in 20 countries. For more information, visit www.aptar.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230220005172/en/

Investor Relations Contact:

Mary Skafidas

mary.skafidas@aptar.com

347-351-6407

Media Contact:

Katie Reardon

katie.reardon@aptar.com

815-479-5671

Source: AptarGroup, Inc.

FAQ

Who is Julie Xing and what is her role at Aptar?

Julie Xing has joined AptarGroup, Inc. as a member of its Board of Directors, bringing over 20 years of experience in pharmaceuticals and healthcare.

When was Julie Xing appointed to Aptar's Board of Directors?

Julie Xing's appointment was announced on February 20, 2023.

What experience does Julie Xing bring to Aptar?

Julie has extensive experience in global markets, having held leadership positions at Mundipharma, Envista Holdings, and Eli Lilly.

What is Aptar's stance on board diversity?

Aptar's Board features 45% women and 27% persons of color, showcasing a commitment to diversity and gender equality.

What is AptarGroup, Inc. known for?

AptarGroup, Inc. is a global leader in drug delivery, consumer product dispensing, and active material science solutions.